Top 10 European Biotech Companies by Pipeline

Copenhagen-based Novo Nordisk became Europe's most valuable company in 2024 with a €560 billion market cap, driven by GLP-1 diabetes and obesity drugs Ozempic and Wegovy generating combined revenues of $21 billion. Its pipeline includes 40+ phase III programmes covering cardiovascular disease, NASH, Alzheimer's, and rare blood disorders. The company employs 65,000 people and allocated $7.8 billion for R&D in 2025.

Copenhagen-founded Genmab generated DKK 17.4 billion ($2.5 billion) in revenue for 2024, with three approved antibody drugs including Darzalex (daratumumab) for multiple myeloma generating $9 billion in annual sales via a partnership with Johnson & Johnson. Its DuoBody technology platform has created 20+ clinical-stage bispecific antibodies. Genmab employs 2,500 scientists and has a $25 billion market capitalisation.

Brussels-based UCB focuses on neurology and immunology, generating €6.5 billion in revenues in 2024. Its lead drug Bimzelx (bimekizumab) for plaque psoriasis and psoriatic arthritis achieved $1.2 billion in peak sales forecasts within 18 months of launch. UCB has 50+ programmes in its pipeline and invests 26% of revenues into R&D, employing 8,600 people across 40 countries.

Belgian biotech Galapagos repositioned in 2023 following a failed JAK inhibitor programme, redirecting €3.5 billion in cash reserves toward oncology and inflammation. With 6 clinical-stage candidates including ziritaxestat for IPF and GLPG3121 for AML, the company is executing one of the largest pipeline rebuilds in European biotech history. Its target acquisition of CellPoint for CAR-T manufacturing was valued at €1.35 billion.

Hamburg-based Evotec provides integrated drug discovery and development services, generating €870 million in revenues in 2024 while maintaining 14 equity partnerships with pharma majors including Bayer, Bristol-Myers Squibb, and Sanofi. Its iPSC disease modelling platform has screened 250 billion compounds. Evotec employs 5,400 scientists and operates 17 labs across Europe and the US.

Belgium-headquartered argenx reached €2.9 billion in revenue in 2024 following the global approval of efgartigimod (Vyvgart) for generalised myasthenia gravis, the first FcRn antagonist approved anywhere. The drug achieved $1.9 billion in its first full year on market. argenx has 10 clinical programmes targeting IgG-mediated autoimmune diseases and a $30+ billion market capitalisation.

Copenhagen-based Bavarian Nordic became the world's only approved mpox (monkeypox) vaccine supplier with Jynneos generating DKK 7.2 billion ($1 billion) in revenues in 2024. The company signed a $1.1 billion contract with the US government in 2022 and supplied 6 million doses to WHO during the 2022 outbreak. Its RSV vaccine Abrysvo (licensed to Pfizer) reached $890 million in first-year sales.

Tubingen-based CureVac is rebuilding its mRNA pipeline after its COVID-19 vaccine failed in Phase 3, partnering with GSK on a $1.4 billion deal to develop a portfolio of mRNA vaccines across influenza, rabies, and COVID variants. The company has 12 active programmes and raised €1.6 billion including $300 million from the German government. Its LASER technology claims 70% improved protein expression vs competitors.

Copenhagen-based Zealand Pharma specialises in peptide-based medicines, generating DKK 3.4 billion ($500 million) in 2024 revenues from its petide GLP-1/glucagon co-agonist dasiglucagon for hypoglycaemia prevention. Its obesity drug survodutide showed 19% weight reduction in Phase 2 trials, positioning Zealand as a credible challenger in the GLP-1 space. The company employs 600 scientists across Copenhagen and New Jersey.

Copenhagen-based Novo Nordisk became Europe's most valuable company in 2024 with a €560 billion market cap, driven by GLP-1 diabetes and obesity drugs Ozempic and Wegovy generating combined revenues of $21 billion. Its pipeline includes 40+ phase III programmes covering cardiovascular disease, NASH, Alzheimer's, and rare blood disorders. The company employs 65,000 people and allocated $7.8 billion for R&D in 2025.

Copenhagen-founded Genmab generated DKK 17.4 billion ($2.5 billion) in revenue for 2024, with three approved antibody drugs including Darzalex (daratumumab) for multiple myeloma generating $9 billion in annual sales via a partnership with Johnson & Johnson. Its DuoBody technology platform has created 20+ clinical-stage bispecific antibodies. Genmab employs 2,500 scientists and has a $25 billion market capitalisation.

Brussels-based UCB focuses on neurology and immunology, generating €6.5 billion in revenues in 2024. Its lead drug Bimzelx (bimekizumab) for plaque psoriasis and psoriatic arthritis achieved $1.2 billion in peak sales forecasts within 18 months of launch. UCB has 50+ programmes in its pipeline and invests 26% of revenues into R&D, employing 8,600 people across 40 countries.

Belgian biotech Galapagos repositioned in 2023 following a failed JAK inhibitor programme, redirecting €3.5 billion in cash reserves toward oncology and inflammation. With 6 clinical-stage candidates including ziritaxestat for IPF and GLPG3121 for AML, the company is executing one of the largest pipeline rebuilds in European biotech history. Its target acquisition of CellPoint for CAR-T manufacturing was valued at €1.35 billion.

Hamburg-based Evotec provides integrated drug discovery and development services, generating €870 million in revenues in 2024 while maintaining 14 equity partnerships with pharma majors including Bayer, Bristol-Myers Squibb, and Sanofi. Its iPSC disease modelling platform has screened 250 billion compounds. Evotec employs 5,400 scientists and operates 17 labs across Europe and the US.

Belgium-headquartered argenx reached €2.9 billion in revenue in 2024 following the global approval of efgartigimod (Vyvgart) for generalised myasthenia gravis, the first FcRn antagonist approved anywhere. The drug achieved $1.9 billion in its first full year on market. argenx has 10 clinical programmes targeting IgG-mediated autoimmune diseases and a $30+ billion market capitalisation.

Copenhagen-based Bavarian Nordic became the world's only approved mpox (monkeypox) vaccine supplier with Jynneos generating DKK 7.2 billion ($1 billion) in revenues in 2024. The company signed a $1.1 billion contract with the US government in 2022 and supplied 6 million doses to WHO during the 2022 outbreak. Its RSV vaccine Abrysvo (licensed to Pfizer) reached $890 million in first-year sales.

Tubingen-based CureVac is rebuilding its mRNA pipeline after its COVID-19 vaccine failed in Phase 3, partnering with GSK on a $1.4 billion deal to develop a portfolio of mRNA vaccines across influenza, rabies, and COVID variants. The company has 12 active programmes and raised €1.6 billion including $300 million from the German government. Its LASER technology claims 70% improved protein expression vs competitors.

Copenhagen-based Zealand Pharma specialises in peptide-based medicines, generating DKK 3.4 billion ($500 million) in 2024 revenues from its petide GLP-1/glucagon co-agonist dasiglucagon for hypoglycaemia prevention. Its obesity drug survodutide showed 19% weight reduction in Phase 2 trials, positioning Zealand as a credible challenger in the GLP-1 space. The company employs 600 scientists across Copenhagen and New Jersey.